Susvimo noninferior to monthly ranibizumab with similar efficacy

The Port Delivery System with ranibizumab was noninferior and had similar efficacy to monthly ranibizumab injections for the treatment of neovascular age-related macular degeneration, according to results from the Archway trial.
The novel treatment delivery method, which was approved by the FDA in October 2021 and is now known as Susvimo (Genentech), allows ranibizumab to be continuously delivered into the vitreous via a refillable ocular implant, reducing the treatment and monitoring burden.
The phase 3 open-label, randomized, visual acuity assessor-masked noninferiority and equivalence

The Port Delivery System with ranibizumab was noninferior and had similar efficacy to monthly ranibizumab injections for the treatment of neovascular age-related macular degeneration, according to results from the Archway trial.
The novel treatment delivery method, which was approved by the FDA in October 2021 and is now known as Susvimo (Genentech), allows ranibizumab to be continuously delivered into the vitreous via a refillable ocular implant, reducing the treatment and monitoring burden.
The phase 3 open-label, randomized, visual acuity assessor-masked noninferiority and equivalence